Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) EBIT (2022 - 2025)

Historic EBIT for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to -$43.1 million.

  • Stoke Therapeutics' EBIT fell 4362.23% to -$43.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.2 million, marking a year-over-year increase of 12318.44%. This contributed to the annual value of -$101.4 million for FY2024, which is 1167.61% up from last year.
  • As of Q3 2025, Stoke Therapeutics' EBIT stood at -$43.1 million, which was down 4362.23% from -$27.3 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' EBIT registered a high of $111.2 million during Q1 2025, and its lowest value of -$43.1 million during Q3 2025.
  • Its 4-year average for EBIT is -$18.6 million, with a median of -$27.2 million in 2023.
  • The largest annual percentage gain for Stoke Therapeutics' EBIT in the last 5 years was 49207.67% (2025), contrasted with its biggest fall of 4362.23% (2025).
  • Quarter analysis of 4 years shows Stoke Therapeutics' EBIT stood at -$27.2 million in 2022, then dropped by 8.87% to -$29.6 million in 2023, then skyrocketed by 53.85% to -$13.7 million in 2024, then tumbled by 215.62% to -$43.1 million in 2025.
  • Its last three reported values are -$43.1 million in Q3 2025, -$27.3 million for Q2 2025, and $111.2 million during Q1 2025.